IFP Advisors Inc Increases Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

IFP Advisors Inc lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 150.4% in the second quarter, Holdings Channel.com reports. The firm owned 4,673 shares of the biotechnology company’s stock after buying an additional 2,807 shares during the period. IFP Advisors Inc’s holdings in Sarepta Therapeutics were worth $85,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. State of Alaska Department of Revenue boosted its holdings in shares of Sarepta Therapeutics by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company’s stock worth $713,000 after purchasing an additional 285 shares during the period. State of Michigan Retirement System boosted its holdings in shares of Sarepta Therapeutics by 1.3% in the 1st quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock worth $1,461,000 after purchasing an additional 300 shares during the period. Louisiana State Employees Retirement System boosted its holdings in Sarepta Therapeutics by 1.1% during the 1st quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the biotechnology company’s stock valued at $1,710,000 after acquiring an additional 300 shares during the period. Ancora Advisors LLC boosted its holdings in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 300 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in Sarepta Therapeutics by 5.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 358 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SRPT. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Guggenheim restated a “buy” rating and set a $22.00 price objective on shares of Sarepta Therapeutics in a report on Monday, September 15th. Leerink Partners boosted their price objective on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a report on Tuesday, September 9th. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 target price on the stock in a research report on Tuesday, July 29th. Finally, Mizuho reaffirmed a “neutral” rating and set a $14.00 target price (down from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Eight research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and seven have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $34.42.

Sarepta Therapeutics Trading Down 3.6%

Shares of NASDAQ SRPT opened at $22.51 on Monday. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The business has a fifty day simple moving average of $19.61 and a two-hundred day simple moving average of $29.00. The firm has a market cap of $2.20 billion, a PE ratio of -25.87 and a beta of 0.51. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics’s revenue was up 68.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.07 EPS. Analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.